Active material: Meldonium
When ATH: C01EB
CCF: Preparation, improves metabolism and energy supply of tissues
ICD-10 codes (testimony): F10.3, H34, H35.0, H35.6, H36.0, H44.8, i20, I21, I25.1, I42, I50.0, I61, I63, I67.2, I69, Z73.0, Z73.3
When CSF: 01.12.11.05
Manufacturer: GRINDEX AO (Latvia)
Capsules hard gelatin, size №1, white; содержимое капсул – белый кристаллический порошок со слабым запахом, hygroscopic.
| 1 caps. | |
| meldonium (trimetilgidraziniya propionate) | 250 mg |
Excipients: potato starch, colloidal silicon dioxide, calcium stearate.
Ingredients of the capsule shell: gelatin, Titanium dioxide (E171).
10 PC. – блистеры (4) – пачки картонные.
Capsules hard gelatin, size №00, white; содержимое капсул – белый кристаллический порошок со слабым запахом, hygroscopic.
| 1 caps. | |
| meldonium (trimetilgidraziniya propionate) | 500 mg |
Excipients: potato starch, colloidal silicon dioxide, calcium stearate.
Ingredients of the capsule shell: gelatin, Titanium dioxide (E171).
10 PC. – блистеры (2) – пачки картонные.
10 PC. – блистеры (6) – пачки картонные.
Preparation, improves metabolism. Meldonium is a structural analog of gamma-butyrobetaine, substances, It is found in every cell of the human body.
Under conditions of high load Mildronat® It restores the balance between delivery and the need for oxygen cells, eliminating the accumulation of toxic products of metabolism in cells, protecting them from damage; also has a tonic effect. As a result of its use of the body acquires the ability to withstand stress and to quickly restore energy reserves. Because of these properties Mildronat®
used to treat a variety of disorders of the cardiovascular system, blood supply to the brain, and improve physical and mental performance.As a result of reducing the concentration of carnitine is synthesized hard gamma-butyrobetaine, vasodilating properties. In acute ischemic myocardial injury Mildronat® It slows down the formation of necrotic zone, shortens the rehabilitation period.
In heart failure, the drug enhances myocardial contractility, increases exercise tolerance, reduces the frequency of angina attacks.
In acute and chronic ischemic cerebrovascular disorders improves blood circulation in the ischemic focus, It promotes redistribution of blood to the ischemic area.
Effective with vascular and dystrophic pathology of the fundus.
The product eliminates the functional disorders of the nervous system in patients with chronic alcoholism during abstinence syndrome.
Absorption
After oral administration, the drug is rapidly absorbed from the gastrointestinal tract. Bioavailability is about 78%. Cmax plasma achieved through 1-2 h after administration.
Metabolism and excretion
It is metabolized in the body into two major metabolites, that the kidneys. T1/2 is 3-6 hours and was dose-dependent.
- In the complex treatment of coronary artery disease (angina, myocardial infarction), chronic heart failure, dyshormonal cardiomyopathy;
- In the complex treatment of acute and chronic disorders of cerebral circulation (strokes and cerebrovascular insufficiency);
- Impaired performance;
- Physical stress (incl. athletes);
- Abstinence syndrome in chronic alcoholism (in combination with a specific treatment of alcoholism);
- Hemophthalmus, retinal hemorrhages of different etiologies;
- Thrombosis of the central retinal vein and its branches;
- Retinopathy of different etiology (Diabetic, hypertension).
Due to the possibility of the exciting effect of the drug is recommended in the first half of the day.
At cardiovascular diseases in the complex therapy drug prescribed oral dose 0.5-1 g / day, multiplicity of application 1-2 times / day. A course of treatment - 4-6 weeks.
At cardialgia on background dyshormonal myocardial dystrophy Mildronat® appointed interior 250 mg 2 times / day. A course of treatment - 12 days.
At violation of cerebral circulation in the acute phase of the drug is prescribed in / (в соответствующей лекарственной форме – по 500 mg 1 times / day for 10 days), then go to the reception of the drug inside 0.5-1 g / day. Общий курс терапии – 4-6 weeks.
At chronic disorders cerebral circulation of the drug is taken orally 0.5-1 g / day. Общий курс терапии – 4-6 weeks. Repeated courses administered individually 2-3 per year.
At mental and physical exertion appointed interior 250 mg 4 times / day. A course of treatment - 10-14 days. If necessary, repeat the treatment after 2-3 of the week.
Athletes recommend the use of 0.5-1 g 2 times / day before workouts. Продолжительность курса в подготовительный период – 14-21 day, в период соревнований – 10-14 days.
At alcoholism drug appointed interior 500 mg 4 times / day. A course of treatment 7-10 days.
Cardio-vascular system: rarely - tachycardia, changes in blood pressure.
CNS: редко – психомоторное возбуждение.
From the digestive system: редко – диспептические симптомы.
Allergic reactions: редко – кожный зуд, redness, rash, edema.
- Increased intracranial pressure (incl. in violation of the venous outflow, intracranial tumors);
- Childhood and adolescence up 18 years;
- Hypersensitivity to the drug.
FROM caution used for diseases of the liver and / or kidney, especially for a long time.
Safety of Mildronate® during pregnancy has not been proven. To avoid possible adverse effects on the fetus drug should not be administered during pregnancy.
Unknown, whether the drug is released in breast milk. If necessary, use Mildronate® lactation breastfeeding should be discontinued.
With careful use of the drug for a long time in patients with chronic liver disease and kidney failure.
Many years of experience in the treatment of acute myocardial infarction and unstable angina in the cardiology departments shows, that Mildronat® not a first-line drug for acute coronary syndrome.
Use in Pediatrics
In children and adolescents under the age of 18 years the efficacy and safety Mildronate® in the form of capsules and injectable solution is not installed.
Effects on ability to drive vehicles and management mechanisms
Data on adverse effects Mildronate® psychomotor speed not available.
Cases of overdose Mildronate® not disclosed, the drug has low toxicity and does not cause side effects, hazardous to the health of patients.
In a joint application Mildronat® enhances the effect of antianginal drugs, Some antihypertensive drugs, cardiac glycosides.
Mildronat® It can be combined with antianginal drugs, anticoagulants and antiplatelet, antiarrhythmics, diuretic, bronholitikami.
In a joint application with Mildronate® nitroglycerin, Nifedipine, alpha-blockers, antihypertensives and peripheral vasodilators may develop mild tachycardia, hypotension (Caution should be exercised when using this combination).
The drug is released under the prescription.
The drug should be stored out of reach of children, dry place at temperatures no higher than 25 ° C. Shelf life - 4 year.
This site uses cookies and services to collect technical data from visitors to ensure performance and improve the quality of service.. By continuing to use our site, you automatically agree to the use of these technologies.
Read More